DOI:

Editorial

Patrick W. Serruys, Editor-in-chief

Our EuroIntervention adventure is now entering its second year and we take great pride in welcoming you to an issue which we hope you will find as exciting and interesting as we do. Like everything in our relatively young specialty, this is a fruit of the labour and vision of many. Collaboration and vision is what has made what we are doing today possible and that is why we continue to remember with great respect the early years of our work, with first hand accounts by Drs. Roubin and Sousa of their “First Twenty years of Stenting”.

But as you know, we do not sit on our laurels. Progress, and the problems we need to address move us on and we invite you to examine the challenges of unified European speciality training by reading the proposals of Working Group 10 of the European Society of Cardiology, participants in – and regular contributors to – our journal.

One of our key articles is from Marie-Claude Morice introducing us to the latest from JUPITER II. This is the randomized trial comparing the performance of tacrolimus-eluting stents (TES) with equivalent carbon-coated stents and involves over 300 patients with de novo coronary stenoses. We have another article discussing the ERACI III study, which extends the results of the excellent earlier ERACI trials to the widespread use of DES in today’s clinical practice, comparing a non-randomized cohort to a previously published patient population.

EuroIntervention then turns toward the ongoing concern with diabetes. In an article by Keith Dawkins, we have a reflection on the benefit of TAXUS stents over bare metal stents in this high-risk group for restenosis. Though the paper is essentially a meta-analysis, it is not without its hands-on side, offering practical information on how to optimize therapy in diabetic patients requiring pharmacotherapy. Another article by Carlos Macaya analyses existing studies, this time focusing on the subset analysis of diabetic patients enrolled in ARTS-I and II. Adverse outcomes of the diabetic patients vs non-diabetic patients are shown, demonstrating that overall MACCE rates in diabetic patients are significantly higher. We will continue addressing these problems in upcoming issues of our journal.

There are articles and technical reports on the controversial area of assist devices in high-risk PCI. Special case reports on percutaneous ventricular restoration, with an accompanying technical report of a world premiere device… and additional information – including videos – of these devices and much more on our increasingly popular website, do not forget to join us there.

And of course this issue is coming to you at the same time as the EuroPCR, which needs no introduction. As Jean Marco says in his editorial, “innovation is the path” we have chosen to follow. And it is an innovation based on our work together, on our ability to communicate, on our commitment to clarity and ethics and we are happy that EuroIntervention is now an essential part of this endeavour.

Volume 2 Number 1
May 20, 2006
Volume 2 Number 1
View full issue


Key metrics

Suggested by Cory

Editorial

10.4244/EIJ-E-25-00025 Aug 18, 2025
Does a positive bubble study after PFO closure matter: is it much ado about nothing or an indication for reintervention?
Horlick E and Abrahamyan L
free

Letter to the editor

10.4244/EIJ-D-25-00472 Aug 18, 2025
Letter: Complex PCI in severe aortic stenosis: high risk, low reward?
Ktenopoulos N et al

Editorial

10.4244/EIJ-E-25-00036 Aug 18, 2025
“He who has eyes to see, let him see”
Garcia-Garcia H
free

Letter to the editor

10.4244/EIJ-D-25-00542 Aug 18, 2025
Reply: Complex PCI in severe aortic stenosis: high risk, low reward?
Munafò A and Montalto C

Original Research

10.4244/EIJ-D-25-00131 Aug 18, 2025
SESAME technique: septal scoring along the midline endocardium
McCabe J et al
Trending articles
95.75

State-of-the-Art

10.4244/EIJ-D-24-00066 Apr 21, 2025
Management of complications after valvular interventions
Bansal A et al
free
76.8

State-of-the-Art

10.4244/EIJ-D-23-00840 Sep 2, 2024
Aortic regurgitation: from mechanisms to management
Baumbach A et al
free
62.15

Image – Interventional flashlight

10.4244/EIJ-D-22-00074 Jun 3, 2022
Transcatheter aortic valve repair for aortic regurgitation with the Cusper device
Feld Y et al
free
58.2

Clinical research

10.4244/EIJ-D-23-00344 Sep 18, 2023
Clinical outcomes of TAVI with the Myval balloon-expandable valve for non-calcified aortic regurgitation
Sanchez-Luna JP et al
free
49.1

Original Research

10.4244/EIJ-D-25-00331 May 21, 2025
One-month dual antiplatelet therapy followed by prasugrel monotherapy at a reduced dose: the 4D-ACS randomised trial
Jang Y et al
open access
49.1

Original Research

10.4244/EIJ-D-25-00331 Jul 21, 2025
One-month dual antiplatelet therapy followed by prasugrel monotherapy at a reduced dose: the 4D-ACS randomised trial
Jang Y et al
open access
31.1

Expert Review

10.4244/EIJ-D-24-00535 May 5, 2025
Catheter-based techniques for pulmonary embolism treatment
Costa F et al
X

PCR
Impact factor: 9.5
2024 Journal Citation Reports®
Science Edition (Clarivate Analytics, 2025)
Online ISSN 1969-6213 - Print ISSN 1774-024X
© 2005-2025 Europa Group - All rights reserved